Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory

Yan-Jun Xiang1,2†, Kang Wang1†, Yi-Tao Zheng2†, Shuang Feng3†, Hong-Ming Yu1, Xiao-Wei Li4, Xi Cheng3, Yu-Qiang Cheng1, Jin-Kai Feng1, Li-Ping Zhou1, Yan Meng3, Jian Zhai4, Yun-Feng Shan2* and Shu-Qun Cheng1,2*

1 Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China, 2 Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China, 3 Department of Radiotherapy, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China, 4 Department II of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China

Background and Aims: Patients with intermediate-stage hepatocellular carcinoma (HCC) who are refractory to transarterial chemoembolization (TACE) have a poor prognosis. This study aimed to explore whether stereotactic body radiation therapy (SBRT) combined with PD-1 inhibitors could improve the clinical outcomes of such patients.

Methods: This retrospective cohort study included patients with intermediate-stage HCC who were diagnosed with TACE refractoriness between January 2019 and December 2020 in the Eastern Hepatobiliary Surgery Hospital and the First Affiliated Hospital of Wenzhou Medical University. The patients were divided into two groups: (1) those who switched from TACE to receive stereotactic body radiotherapy (SBRT) combined with PD-1 inhibitors; (2) those who continued TACE treatment and added PD-1 inhibitors. Progression-free survival (PFS), overall survival (OS), and tumour response were assessed in both groups after becoming refractory to TACE treatment.

Results: Of the seventy-six patients included in this study, the median PFS was 19.6 months in the SBRT-IO group (n=31) and 10.1 months in the TACE-IO group (n=45, p<0.05). The SBRT-IO group also had a significantly higher OS than the TACE-IO group (p<0.05). The objective response rate (ORR) and disease control rate (DCR) were also better in the SBRT-IO group (ORR, 71.0% vs. 15.6%, OR=8.483, 95% CI 3.319-21.680, P < 0.001; DCR, 80.6% vs. 31.1%, OR=9.226, 95% CI 3.096-27.493, P < 0.001).

Conclusions: SBRT combined with a PD-1 inhibitor improves PFS and OS in TACE-refractory patients with intermediate-stage HCC. Therefore, this therapy is a suitable option in cases of TACE treatment failure.

Keywords: hepatocellular carcinoma, stereotactic body radiation therapy, transarterial chemoembolization refractory, immunotherapy, combination therapy
INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fourth leading cause of cancer-related death worldwide (1). Since patients with early-stage HCC are usually asymptomatic, approximately half of them are diagnosed at intermediate to advanced stages and cannot undergo radical treatment (2–5).

For patients with intermediate-stage HCC, transarterial chemoembolization (TACE) is recommended as the standard treatment by many guidelines (6–9). However, the efficacy of TACE alone is limited, and some patients are diagnosed as refractory to TACE (10, 11). Most guidelines recommend starting systemic therapy as soon as TACE refractoriness occurs (6, 8, 9). As a new systemic therapeutic drug, PD-1 inhibitors show synergistic effects when combined with TACE (12, 13). In other words, the combined use of PD-1 inhibitors may improve the prognosis of TACE-refractory patients.

Stereotactic body radiotherapy (SBRT) is a newer treatment with evidence of promising local control for patients with HCC (14–16). For early- and intermediate-stage HCC patients, SBRT is a safe alternative to TACE and provides no inferior or even better local control and overall survival (OS) than TACE (17, 18). Furthermore, there is synergy in the use of radiotherapy in combination with PD-1 inhibitors (19, 20). Therefore, we speculate that SBRT combined with a PD-1 inhibitor may be an effective alternative treatment for TACE-refractory patients.

In this study, we investigated whether TACE-refractory patients should be administered PD-1 inhibitors to maintain TACE treatment or should be switched to SBRT plus PD-1 inhibitors, as reports on these two treatments are currently lacking. We conducted this retrospective study to evaluate the efficacy and safety of the above two therapies in intermediate HCC patients who are refractory to TACE treatment.

METHODS

Patients

A retrospective study of consecutive HCC patients was conducted at the Eastern Hepatobiliary Surgery Hospital and the First Affiliated Hospital of Wenzhou Medical University from 2019 to 2020. This study was approved by the Institutional Ethics Committee of each centre. As patient identities were anonymized, the requirement for informed consent was waived by the ethics committee.

The inclusion criteria were patients with (1) HCC diagnosed by histopathology, computed tomography (CT) or magnetic resonance imaging (MRI), (2) good liver function (Child-Pugh A or B7, score <= 7), (3) BCLC stage B, (4) TACE, and (5) TACE refractoriness. The exclusion criteria were patients with (1) previous locoregional or systemic therapy, (2) recurrent HCC, (3) a history of other cancers, and (4) incomplete clinical data.

TACE and SBRT

The optimal treatment modality was discussed and determined by the multidisciplinary team at each institution. Locoregional therapies, including surgery or alternative approaches (SBRT or TACE), are considered based on the individual patient’s circumstances (tumour size, liver function, and proximity to organs at risk). The final decision is made by the patient after the benefits of various treatment modalities, as well as associated side effects and costs, have been fully explained.

TACE was performed as previously described using the Seldinger’s technique (21). Briefly, the tumour-feeding artery was first identified by angiography, and after cannulation of the hepatic artery, doxorubicin hydrochloride, pirarubicin and lipiodol were injected through the catheter. Post TACE evaluation and follow-up were performed every 6–8 weeks. The diagnostic criteria of TACE refractoriness were based on the definition proposed by the Japan Society of Hepatology (JSH) and the Liver Cancer Study Group of Japan (insufficient response of the treated tumour after two procedures) (22).

SBRT was performed by CyberKnife® (Accuray Cyberknife, VSI), with a total of 24–45 Gy in 3–5 fractions. The patients who received SBRT were first implanted with at least 3 gold fiducials inside or adjacent to the tumour under CT (Philips Brilliance CT Big Bore Oncology) guidance, and the gold fiducials were relatively stable and immobile after seven days, with localization simulated under CT. The images were subsequently transferred to the treatment planning system, and the target area was then delineated by a radiologist. A 2.5 mm marginal expansion of the gross tumour volume (defined as radiologically evident gross disease) formed the planning target volume. The physiatrist developed the treatment plan while defining normal tissue dose ranges. Dose-volume histograms were generated for all target volumes and critical normal structures. Dose constraints for organs at risk were determined based on the American Association of Physicists in Medicine guidelines in AAPM Task Group 101 (23).

PD-1 Inhibitors

All included patients were treated with PD-1 inhibitors after being diagnosed as refractory to TACE treatment. PD-1 inhibitors included toripalimab (72.4%) and sintilimab (27.6%) (Supplementary Table 1), both of which have been reported to be effective in patients with HCC (24–31). Toripalimab was administered at a dose of 3 mg/kg by body weight every 2 weeks; sintilimab was administered at a dose of 200 mg every three weeks. The specific doses and protocols used were strictly in accordance with the instructions for use. PD-1 inhibitors were all administered intravenously; if low-grade infusion reactions occurred, drip plasticity was reduced or dosing was suspended until the symptoms resolved, at which time the medication was resumed while the patient remained under close observation. PD-1 inhibitors were continued until intolerable toxicity occurred.

Abbreviations: HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; SBRT, stereotactic body radiation therapy; OS, overall survival; CT, computed tomography; MRI, magnetic resonance imaging; JSH, Japan Society of Hepatology; PFS, progression-free survival; TRAEs, treatment-related adverse events; HR, hazard ratio; OR, odds ratio; ORR, objective response rate; DCR, disease control rate; DAMPs, damage-associated molecular patterns.
Follow-Up and Assessment
All patients visited the outpatient clinic for follow-up every 1-3 months. At each follow-up visit, a routine physical examination, laboratory blood tests, and abdominal ultrasound or enhanced CT/MRI were performed. The primary outcome of this study was progression-free survival (PFS), which was defined as the time from the initiation of PD-1 inhibitors to tumor progression, death from any cause, or the most recent follow-up. The secondary endpoints included overall survival (OS), objective response rate (ORR) and treatment-related adverse events (TRAEs). Tumor progression included progression of treated lesion, and new lesions within or outside the liver. OS was defined as the time from the initiation of PD-1 inhibitor use until the date of death from any cause or the date of the most recent follow-up visit. Disease control rate (DCR) was defined as the percentage of patients attained complete response, partial response or stable disease. Assessment of tumor progression was based on modified Response Evaluation Criteria in Solid Tumors criteria (mRECIST).

TRAEs were recorded from the initiation of PD-1 inhibitor use and obtained from clinical visit notes or medical records. TRAEs were assessed according to the criteria of the common terminology criteria for adverse events (CTCAE, version 5.0). If multiple instances of the same type of toxicity occurred, the highest grade for each patient in a given category was adopted.

Statistical Analysis
All clinical data were analyzed using IBM SPSS Statistics 24 (New York, NY, USA) or R 4.0 software (http://www.r-project.org/). Student’s t-test was used to compare continuous variables, and the χ2 test or Fisher exact test was used to compare categorical variables. Survival curves were calculated using the Kaplan–Meier method and compared using the log-rank test. The hazard ratio (HR) was calculated by Cox regression models. Univariate Cox regression analysis was used to evaluate the significance of variable in the entire cohort. All variables which were significantly related to PFS (p<0.05) were included in the multiple Cox regression analysis. The odds ratio (OR) was calculated by logistic regression models. P < 0.05 was considered to indicate a significant difference.

RESULTS
Patient Characteristics and Treatments
A flow diagram of the present study is shown in Figure 1. Of the 76 patients at the Eastern Hepatobiliary Surgery Hospital and the First Affiliated Hospital of Wenzhou Medical University with complete clinical and follow-up data, 45 (59.2%) patients received TACE-IO therapy, and 31 (47.3%) received SBRT-IO therapy. Table 1 summarizes the baseline features of these patients. There were no significant differences at baseline between the two groups, including age, sex, HBsAg, maximum tumor size, number of tumors, alpha-fetoprotein concentration, Des-gamma-carboxy prothrombin, total bilirubin, albumin, albumin-bilirubin grade, prothrombin time, glucose, creatinine or platelet count.

The median follow-up was 10 and 11 months in the TACE-IO and SBRT-IO groups, respectively. The median cycle of PD-1 inhibitor use was six in both groups. Total 63 lesions were irradiated in SBRT-IO arm (Single lesion, n=5; Two lesions, n=20; Three lesions, n=6). Of the 76 patients enrolled in the study, 41 patients died during the study (31 in the TACE-IO group and 10 in the SBRT-IO group), 29 were alive (10 in the TACE-IO group and 19 in the SBRT-IO group), and 6 were lost to follow-up (4 in the TACE-IO group and 2 in the SBRT-IO group).

Efficacy Outcomes
The median PFS was 19.6 months (95% CI 13.1-26.1) in the SBRT-IO group and 10.1 months (95% CI 7.3-12.9) in the TACE-IO group. The median OS was 14.1 months in the TACE-IO group.
group and was not reached in the SBRT-IO group. The 1-year OS and PFS rates of the SBRT-IO group were 71.5% and 64.8%, respectively, while those of the TACE-IO group were 54.2% and 40.7%, respectively. SBRT significantly prolonged PFS relative to TACE (Figure 2A, P < 0.05). In the entire cohort, treatment with SBRT-IO was a significantly unfavourable factor for PFS (HR=0.372, 95% CI 0.186-0.745, P=0.005), along with ALBI grade 2 (Table 2). Similarly, as shown in Figure 2B, SBRT significantly prolonged OS relative to TACE (HR = 0.375, 95% CI 0.182-0.773, P < 0.05).

Table 3 summarizes the best tumour responses for all HCC patients. According to mRECIST, the ORR in the SBRT-IO group was significantly higher than that in the TACE-IO group (71.0% vs. 15.6%, OR=8.483, 95% CI 3.319-21.680, P < 0.001). The DCR in the SBRT-IO group was also significantly higher than that in the TACE-IO group (80.6% vs. 31.1%, OR=9.226, 95% CI 3.096-27.493, P < 0.001).

First Site of Progressive Disease and Treatment on Progression
Forty-five patients had progressed at the time of analysis. Thirty-one (68.9%) patients in the TACE-IO cohort progressed, 26 (57.8%) of whom had intrahepatic progression; Fourteen (45.2%) patients progressed in the SBRT-IO cohort, 11 (35.5%) of whom had intrahepatic progression, as detailed in Supplementary Table 2.

Following progressive disease, most patients had more treatment. In the TACE-IO cohort, 27 patients received further treatment, three patients received supportive care due to physical

### Table 1 | Baseline characteristics of study patients.

| Characteristics | TACE-IO (n = 45) | SBRT-IO (n = 31) | P value |
|-----------------|-----------------|-----------------|---------|
| Age, year | | | 0.945 |
| < 65 | 36 (86.2) | 25 (78.8) | | |
| ≥ 65 | 9 (13.8) | 6 (21.2) | | |
| Gender | | | 0.168 |
| Female | 6 (13.8) | 8 (19.2) | | |
| Male | 39 (86.2) | 23 (80.8) | | |
| HBsAg | | | 0.525 |
| Positive | 40 (82.8) | 26 (78.9) | | |
| Negative | 5 (17.2) | 5 (21.1) | | |
| Liver cirrhosis | | | 0.666 |
| Yes | 38 (84.4) | 25 (80.6) | | |
| No | 7 (15.6) | 6 (19.4) | | |
| Child-Pugh | | | 1.000 |
| A | 44 | 31 | | |
| B | 1 | 0 | | |
| Maximum tumour size, cm, median (range) | | | 0.161 |
| 2 | 31 | 20 | | |
| 3 | 10 | 11 | | |
| 4 | 4 | 0 | | |
| AFP, ng/mL | | | 0.137 |
| < 400 | 22 (58.6) | 17 (81.5) | | |
| ≥ 400 | 23 (41.4) | 14 (18.5) | | |
| DCP, mAU/mL | | | 0.555 |
| < 2050 | 26 (65.5) | 20 (73.1) | | |
| ≥ 2050 | 19 (34.5) | 11 (26.9) | | |
| TB, umol/L | | | 0.468 |
| < 18.8 | 27 | 16 | | |
| ≥ 18.1 | 18 | 15 | | |
| Albmin, g/L | | | 0.145 |
| < 35 | 8 | 10 | | |
| ≥ 35 | 37 | 21 | | |
| ALBI grade | | | 0.243 |
| 1 | 25 (55.2) | 13 (53.9) | | |
| 2 | 20 (41.4) | 18 (46.1) | | |
| 3 | 0 | 0 | | |
| PT, sec | | | 0.669 |
| < 13 | 36 | 26 | | |
| ≥ 13 | 9 | 5 | | |
| Glucose, mmol/L | | | 0.337 |
| < 7 | 39 | 29 | | |
| ≥ 7 | 6 | 2 | | |
| Creatinine, umol/L, median | | | 0.222 |
| Platelet, X10⁹, median | | | 0.625 |
| | 66.0 | 61.0 | | |
| | 162.0 | 174.0 | | |

TACE, transcatheter arterial chemoembolization; SBRT, stereotactic body radiation therapy; AFP, alpha-fetoprotein concentration; DCP, Des-gamma-carboxy prothrombin; TB, total bilirubin; ALBI, albumin-bilirubin; PT, prothrombin time.

---

Xiang et al. SBRT-IO for Intermediate-Stage HCC
Frontiers in Oncology | www.frontiersin.org March 2022 | Volume 12 | Article 8396054
deterioration, and one patient refused treatment; In the SBRT-IO cohort, 12 patients received further treatment, one patient received supportive care and one patient refused treatment.

Safety Outcomes
According to CTCAE version 5.0, TRAEs were evaluated during treatment according to their frequency and severity. Almost all patients experienced transient TRAEs after receiving locoregional therapies, which spontaneously resolved. Therefore, we did not analyse and discuss these transient TRAEs.

As shown in Supplementary Table 3, the most common TRAEs at all levels in the TACE-IO group were decreased platelet count (44.4%), decreased albumin (37.8%), and elevated AST (37.8%). In addition, the most common grade 3/4 TRAE was decreased platelet count (6.7%). In the SBRT-IO group, the most common TRAEs were fatigue (54.8%), decreased platelet count (48.4%) and decreased white blood cell (32.3%), and the most common grade 3/4 TRAEs were elevated AST (3.2%) and ALT (3.2%) levels, and hand-foot skin reaction (3.2%). Furthermore, among patients treated with SBRT-IO, none developed classical radiation-induced liver disease, and no treatment-related deaths occurred.

DISCUSSION
In this study, we report for the first time the efficacy of SBRT combined with a PD-1 inhibitor in TACE-refractory patients with intermediate-stage HCC. The results showed that receiving SBRT combined with a PD-1 inhibitor provided a better long-term prognosis and greater tumour control than TACE combined with a PD-1 inhibitor alone for TACE refractory patients. This provides more options for the treatment of patients with BCLC stage B HCC.

TACE is the standard of care for patients with BCLC stage B HCC (6–9), but some patients develop TACE refractoriness and cannot achieve effective tumour control (10, 11). The guidelines recommend that patients start receiving systemic therapy once

| TABLE 2 | Prognostic factors for progression-free survival. |
|-----------------------------|-----------------------------|-----------------------------|
| Progression-free survival   | Univariate analysis         | Multivariate analysis       |
|                            | HR             | 95% CI       | P value | HR             | 95% CI       | P value |
| Age (>65/≤65 years)         | 1.459          | 0.669-3.183  | 0.342   |                |               |         |
| Sex (male/female)           | 2.029          | 0.857-4.808  | 0.108   |                |               |         |
| HBsAg (positive/negative)   | 0.614          | 0.283-1.334  | 0.218   |                |               |         |
| Albumin (>35/≤35 g/dl)      | 0.638          | 0.296-1.373  | 0.250   |                |               |         |
| Total bilirubin (≥17.1/≤17.1 μmol/L) | 2.029          | 0.838-2.773  | 0.167   |                |               |         |
| ALBI grade (2/1)            | 2.234          | 1.200-4.159  | 0.011   | 2.132          | 1.144-3.970  | 0.017   |
| Prothrombin time (≥13/≤13 second) | 0.866          | 0.361-2.076  | 0.747   |                |               |         |
| Creatinine (≥106/≤106 μmol/L) | 1.001          | 0.982-1.021  | 0.896   |                |               |         |
| Blood glucose (≥7/≤7 mmol/L) | 1.031          | 0.401-2.649  | 0.950   |                |               |         |
| Platelet (≥100/≤100 10^9/L) | 0.995          | 0.988-1.003  | 0.216   |                |               |         |
| Alpha fetoprotein (≥400/≤400 ng/mL) | 0.770          | 0.427-1.391  | 0.386   |                |               |         |
| DCP (≥2050/≤2050 mAU/mL)    | 0.730          | 0.396-1.346  | 0.314   |                |               |         |
| Liver cirrhosis (yes/no)    | 0.108          | 0.517-2.255  | 0.838   |                |               |         |
| Tumour number (3/2)         | 1.044          | 0.533-2.042  | 0.901   |                |               |         |
| Tumour number (4/2)         | 3.022          | 0.901-10.141 | 0.073   |                |               |         |
| Maximum tumour size, cm     | 1.126          | 0.575-2.205  | 0.730   |                |               |         |
| Treatment (SBRT-IO/TACE-IO)  | 0.361          | 0.182-0.716  | 0.004   | 0.372          | 0.186-0.745  | 0.005   |

ALBI, albumin-bilirubin; DCP, Des-gamma-carboxy prothrombin; SBRT, stereotactic body radiation therapy; TACE, transcatheter arterial chemoembolization.
they are diagnosed with TACE refractoriness (6, 8, 9). However, a recent international expert panel of International Society of Multidisciplinary Interventional Oncology consensus statement and a survey by Chinese College of Interventionalists indicated that repeated TACE especially TACE based combination therapy can also achieve survival benefit in patients refractory to TACE (32–35). Meanwhile, PD-1 inhibitors have been increasingly explored as representative agents for immunotherapy, the possible mechanism underlying the benefit of TACE combined with a PD-1 inhibitor was revealed: TACE could decrease the ratio of CD4+/CD8+ cells and increase the level of PD-1 mRNA expression in patients with HCC (12). Therefore, TACE combined with a PD-1 inhibitor might have potential clinical value for patients who are refractory to TACE.

Radiotherapy is limited in its clinical application in these patients because of increased hepatotoxicity. Due to technological advances, SBRT is currently able to safely deliver high-dose radiotherapy to HCC patients, and the American Association for the Study of Liver Diseases guidelines accept SBRT as one of the treatment for HCC (7). A previous study showed that patients with intermediate- and advanced-stage HCC can also benefit from SBRT (36), and another study demonstrated that the 2-year local control rate reached 61-81% in patients with BCLC stage B HCC (36), and another study demonstrated that the 2-year local control rate reached 61-81% in patients with BCLC stage B HCC. Therefore, TACE combined with a PD-1 inhibitor might have potential clinical value for patients who are refractory to TACE.

In conclusion, our data strongly support the fact that intermediate-stage HCC patients who are refractory to TACE might benefit from the addition of a PD-1 inhibitor or from the switch to SBRT combined with a PD-1 inhibitor. In this study, which enrolled 76 patients proven to be refractory to PD-1 inhibitor TACE treatment, the SBRT-IO group (n = 31) had a median PFS of 19.6 months (95% CI 13.1-26.1), which was significantly higher than the TACE-IO group (n = 45) with a median PFS of 10.1 months (95% CI 7.3-12.9, P < 0.001). The 1-year OS and 1-year PFS rates in the SBRT-IO group were 71.5% and 64.8%, and the ORR and DCR were 71.0% and 80.6%, respectively. The 1-year OS and 1-year PFS rates in the TACE-IO group were 54.2% and 40.7%, and the ORR and DCR were 15.6% and 31.1%, respectively. Compared with TACE-IO, SBRT-IO significantly prolonged PFS (HR=0.375, 95% CI 0.182-0.773, P < 0.001) and OS (HR = 0.375, 95% CI 0.182-0.773, P < 0.001) and resulted in a better ORR (OR=8.483, 95% CI 3.319-21.680, P < 0.001) and DCR (OR = 9.226, 95% CI 3.096-27.493, P < 0.001) in TACE-refractory patients. Furthermore, the median OS of the TACE-IO group was similar to that of TACE-refractory patients as previously reported by Kudo et al. (41); therefore, whether adding a PD-1 inhibitor can improve the prognosis for TACE-refractory patients requires further study.

In addition to efficacy, we analysed the TRAEs associated with SBRT plus PD-1 inhibitors. The most common TRAEs were decreased WBC (67.7%), fatigue (54.8%) and decreased platelet count (48.4%), and the most common grade 3/4 TRAEs were decreased WBC (6.5%), elevated AST (3.2%) and ALT (3.2%) levels and hand-foot skin reaction (3.2%), with no unexpected TRAEs occurring. Therefore, SBRT-IO is an effective and safe treatment for intermediate-stage HCC patients who are refractory to TACE treatment.

We must acknowledge that our study had some limitations. First, this is a retrospective study with inherent defects. Second, this was a study conducted in HBV-endemic China, which may have influenced the results. Third, the sample size included in this study was small, and the number of tumours per patient was small (fewer than 5). A prospective study is therefore needed to confirm our findings.

In conclusion, our data strongly support the fact that switching to a combination of SBRT and a PD-1 inhibitor improves clinical outcomes, as evidenced by the increased PFS and OS in intermediate-stage HCC patients who are refractory to TACE. Repeated TACE treatments may cause resistance to systemic therapy and result in the deterioration of liver function. Therefore, the combination of SBRT with a PD-1 inhibitor is a safe and effective alternative that warrants consideration by clinicians.

### TABLE 3 | Best tumour response.

| TACE-IO (n=45) | SBRT-IO (n=31) | P value |
|---------------|---------------|---------|
| CR            | 0             | 11(35.5)|
| PR            | 7 (15.6)      | 11 (35.5)|
| SD            | 7 (15.6)      | 3 (9.7) |
| PD            | 31 (68.9)     | 6 (19.4)|
| ORR           | 7 (15.6)      | 22 (71.0)| <0.001 |
| DCR           | 14 (31.1)     | 25 (80.6)| <0.001 |

TACE, transcatheter arterial chemoembolization; SBRT, stereotactic body radiation therapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
This study was approved by the Institutional Ethics Committees of the Eastern Hepatobiliary Surgery Hospital and the First Affiliated Hospital of Wenzhou Medical University. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHORS CONTRIBUTIONS
Conceptualization: S-QC, Y-FS, and Y-JX. Funding acquisition: S-QC, Y-FS, and Y-JX. Investigation: Y-JX, KW, Y-TZ, SF, H-MY, Y-QC. Resources: S-QC, KW, SF, XC, H-MY, X-WL, L-PZ, JZ, YM. Writing–original draft: Y-JX. Writing–review & editing: S-QC and Y-FS. All authors contributed to the article and approved the submitted version.

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68(6):394–424. doi: 10.3322/caac.21492
2. Bruijx S, Shermenn M. American Association for the Study of Liver Disease. Hepatology. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: An Update. Hepatol Biol (2011) 53(3):1020–2. doi: 10.1002/hep.21499
3. European Association For The Study Of The Liver. European Organisation For Research Treatment Of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J Hepatol (2012) 56(4):908–43. doi: 10.1016/j.jhep.2011.12.001
4. Forrer A, Reig M, Bruijx J. Hepatocellular Carcinoma. Lancet (2018) 391(10127):1301–14. doi: 10.1016/S0140-6736(18)30010-2
5. Bruijx J, Reig M, Shermenn M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterol (2016) 150(4):835–53. doi: 10.1053/j.gastro.2015.12.041
6. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J Hepatol (2018) 69(1):182–236. doi: 10.1016/j.jhep.2018.03.019
7. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatol (2018) 68(2):723–50. doi: 10.1002/hep.29913
8. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2018) 29(Suppl 4):iv238–iv55. doi: 10.1093/annonc/mdy308
9. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma: A 2017 Update. Hepatol Int (2017) 11(4):317–70. doi: 10.1007/s12072-017-9799-9
10. Kim HY, Park JW, Joo I, Jung SJ, An S, Woo SM, et al. Severity and Timing of Progression Predict Refractoriness to Transarterial Chemoembolization in Hepatocellular Carcinoma. J Gastroenterol Hepatol (2012) 27(6):1051–6. doi: 10.1111/j.1440-1746.2011.06963.x
11. Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, et al. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients With Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2. Dig Dis (2017) 35(6):589–97. doi: 10.1159/000480208
12. Guo J, Wang S, Han Y, Jia Z, Wang R. Effects of Transarterial Chemoembolization on the Immunological Function of Patients With Hepatocellular Carcinoma. Oncol Lett (2021) 22(1):554. doi: 10.3892/ol.2021.12815
13. Hiroishi K, Eguchi J, Baba T, Shimazaki T, Ishii S, Hiraide A, et al. Strong CD8 (+) T-Cell Responses Against Tumor-Associated Antigens Prolong the Recurrence-Free Interval After Tumor Treatment in Patients With Hepatocellular Carcinoma. J Gastroenterol (2010) 45(4):451–8. doi: 10.1007/s00535-009-0155-2
14. Bujeid A, Masuey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. J Clin Oncol (2013) 31(13):1631–9. doi: 10.1200/JCO.2012.44.1659
15. Liu E, Stermark MH, Schipper MJ, Balter JM, Kessler ML, Caoli EM, et al. Stereotactic Body Radiation Therapy for Primary and Metastatic Liver Tumors. Transl Oncol (2013) 6(4):442–6. doi: 10.1593/tlo.12448
16. Wahl DR, Stermark MH, Tao Y, Polloom EL, Caoli EM, Lawrence TS, et al. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol (2016) 34(5):452–9. doi: 10.1200/JCO.2015.61.4925
17. Sagir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, et al. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Oncol Radiol Biol Phys (2018) 100(1):122–30. doi: 10.1016/j.ijrobp.2017.09.001
18. Shen PC, Chang WC, Lo CH, Yang JF, Lee MS, Dai YH, et al. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys (2019) 105(2):307–18. doi: 10.1016/j.ijrobp.2019.05.066
19. Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and Stereotactic Ablative Radiotherapy (SABRE): A Curative Approach? Nat Rev Clin Oncol (2016) 13(8):516–24. doi: 10.1038/nrclinonc.2016.30
20. Romano E, Honeychurch J, Illidge TM. Radiotherapy-Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery? Cancers (Basel) (2021) 13(3):457. doi: 10.3390/cancers13030457

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.839605/full#supplementary-material
21. Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, et al. Lenvatinib in Combination With Transarterial Chemoembolization for Treatment of Unresectable Hepatocellular Carcinoma (uHCC): A Retrospective Controlled Study. Hepatol Int (2021) 15(3):663–75. doi: 10.1007/s12072-021-10184-9

22. Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, et al. Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update. Oncology (2014) 87(Suppl 1):22–31. doi: 10.1159/000368142

23. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic Body Radiation Therapy: The Report of AAPM Task Group 101. Med Phys (2010) 37(8):10478–101. doi: 10.1118/1.3438081

24. Fang Y, Liu W, Tang Z, Ji X, Zhou Y, Song S, et al. Monocarboxylate Transporter 4 Inhibition Potentiates Hepatocellular Carcinoma Immunotherapy Through Enhancing T Cell Infiltration and Immune Attack. Hepatology (2022). doi: 10.1002/hep.33248

25. Xu YJ, Lai ZC, He MK, Bu XY, Chen HW, Zhou YM, et al. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. Technol Cancer Res Treat (2021) 20:1533038211063848. doi: 10.1177/1533038211063848

26. X. Xu J, Gu X, Chen L, Wu Q, Li H, et al. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma. Front Immunol (2021) 12:7460790. doi: 10.3389/fimmu.2021.7460790

27. Yuan G, Song Y, Li Q, Hu X, Zang M, Dai W, et al. Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients. Front Immunol (2020) 11:613946. doi: 10.3389/fimmu.2020.613946

28. Chen J, Hu X, Li Q, Dai W, Cheng X, Huang W, et al. Effectiveness and Safety of Toripalimab, Camrelizumab, and Sintilimab in a Real-World Cohort of Hepatitis B Virus Associated Hepatocellular Carcinoma Patients. Ann Transl Med (2020) 8(18):1187. doi: 10.21037/atm-20-6063

29. Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab Plus a Bevacizumab Biosimilar (IBI305) Versus Sorafenib in Unresectable Hepatocellular Carcinoma (ORIENT-32): A Randomised, Open-Label, Phase 2-3 Study. Lancet Oncol (2021) 22(7):977–90. doi: 10.1016/S1470-2045(21)00252-7

30. Cao F, Yang Y, Si T, Lao J, Zeng H, Zhang Z, et al. The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. Front Oncol (2021) 11:783480. doi: 10.3389/fonc.2021.783480

31. Wen L, Zhou C, Chen X, Bai Y, Liang T. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-Tumor Effect of Partial Regression. Front Immunol (2020) 11:2076. doi: 10.3389/fimmu.2020.02076

32. Lu J, Zhao M, Aray J, Zhong BY, Zhu HD, Qi XL, et al. Clinical Practice of Transarterial Chemoembolization for Hepatocellular Carcinoma: Consensus Statement From an International Expert Panel of International Organization of Interventional Oncology (ISMO). Hepatobil Surg Nutr (2021) 10(5):661–71. doi: 10.21037/hbsn-21-260

33. Zhong BY, Wang WS, Zhang S, Zhu HD, Zhang L, Shen J, et al. Re-Evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists. J Clin Transl Hepatol (2021) 9(4):521–7. doi: 10.1218/JCTH.2021.00049

34. Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, et al. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci (2020) 7:690322. doi: 10.3389/fmolb.2020.690322

35. Terzi E, Golferi R, Piscaglia F, Galassi M, Dazzi A, Leoni S, et al. Response Rate and Clinical Outcome of HCC After First and Repeated cTACE Performed “On Demand”. J Hepatol (2012) 57(6):1258–67. doi: 10.1016/j.jhep.2012.07.025

36. Bettiger D, Pinato DJ, Schluthiess M, Sharma R, Rimassa L, Pressiani T, et al. Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients With Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer (2019) 8(4):281–94. doi: 10.1159/000490260

37. Bang A, Dawson LA. Radiotherapy for HCC: Ready for Prime Time? JHEP Rep (2019) 1(2):131–7. doi: 10.1016/j.jhep.2019.05.004

38. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, et al. Stereotactic Body Radiation Therapy for Inoperable Hepatocellular Carcinoma as a Local Salvage Treatment After Incomplete Transarterial Chemoembolization. Cancer (2012) 118(21):5424–31. doi: 10.1002/cncr.27533

39. Chiang CL, Chan ACY, Chiu KWH, Kong FS. Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy. Front Oncol (2019) 9:1157. doi: 10.3389/fonc.2019.01157

40. Zhong L, Wu D, Peng W, Sheng H, Xiao Y, Zhang X, et al. Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma. Front Oncol (2021) 11:686621. doi: 10.3389/fonc.2021.686621

41. Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, et al. Effectiveness of Sorafenib in Patients With Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer (2015) 4(4):253–62. doi: 10.1159/000367743

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xiang, Wang, Zhang, Feng, Yu, Li, Cheng, Cheng, Feng, Zhou, Meng, Zhou, Shan and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.